Paper22472995
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
Dooley KE and 9 others. Clin Pharmacol Ther, 2012. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Papers, record 22472995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22472995
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
- PubMed
- Publication types
- Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Rifampin | Major topic |
| Adult | |
| Area Under Curve | |
| Cytochrome P-450 CYP3A | |
| Female | |
| Humans | |
| Male | |
| Midazolam | |
| Middle Aged |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 1S10 RR 27733 | NCRR NIH HHS | United States | S10RR027733 | PubMed and NIH | NIH RePORTER |
| P30 50410 | PHS HHS | United States | PubMed | PubMed | |
| UL1 RR025005 | NCRR NIH HHS | United States | UL1RR025005 | PubMed and NIH | NIH RePORTER |
| K23 AI080842 | NIAID NIH HHS | United States | K23AI080842 | PubMed and NIH | NIH RePORTER |
| S10 RR027733 | NCRR NIH HHS | United States | S10RR027733 | PubMed and NIH | NIH RePORTER |
| K23AI080842 | NIAID NIH HHS | United States | K23AI080842 | PubMed and NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02563327 | Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis | Background | ClinicalTrials.gov | |
| NCT06253715 | Shortened Regimen for Drug-susceptible TB in Children | Background | ClinicalTrials.gov |
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20147896 | A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20147896 | PubMed |
| 2 | 12241657 | Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. | Lancet | 2002 | https://conductscience.org/library/papers/12241657 | PubMed |
| 3 | 3947503 | Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. | Br J Clin Pharmacol | 1986 | https://conductscience.org/library/papers/3947503 | PubMed |
| 4 | 16480505 | Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. | Ann Clin Microbiol Antimicrob | 2006 | https://conductscience.org/library/papers/16480505 | PubMed |
| 5 | 16109981 | Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. | Am J Respir Crit Care Med | 2006 | https://conductscience.org/library/papers/16109981 | PubMed |
| 6 | 346286 | Clinical pharmacokinetics of rifampicin. | Clin Pharmacokinet | 1978 | https://conductscience.org/library/papers/346286 | PubMed |
| 7 | 18815591 | Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. | Clin Pharmacol Ther | 2009 | https://conductscience.org/library/papers/18815591 | PubMed |
| 8 | 684036 | Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week. | Pharmacol Res Commun | 1978 | https://conductscience.org/library/papers/684036 | PubMed |
| 9 | 18037906 | Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. | Br J Pharmacol | 2008 | https://conductscience.org/library/papers/18037906 | PubMed |
| 10 | 9402947 | Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. | Chem Biol Interact | 1997 | https://conductscience.org/library/papers/9402947 | PubMed |
| 11 | 18723432 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? | Am J Respir Crit Care Med | 2008 | https://conductscience.org/library/papers/18723432 | PubMed |
| 12 | 16251279 | Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16251279 | PubMed |
| 13 | 16580903 | Comparison of midazolam and simvastatin as cytochrome P450 3A probes. | Clin Pharmacol Ther | 2006 | https://conductscience.org/library/papers/16580903 | PubMed |
| 14 | 4087830 | Pharmacokinetics of oral and intravenous rifampicin during chronic administration. | Klin Wochenschr | 1985 | https://conductscience.org/library/papers/4087830 | PubMed |
| 15 | 8549036 | Rifampin drastically reduces plasma concentrations and effects of oral midazolam. | Clin Pharmacol Ther | 1996 | https://conductscience.org/library/papers/8549036 | PubMed |
| 16 | 16574936 | Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. | Am J Respir Crit Care Med | 2006 | https://conductscience.org/library/papers/16574936 | PubMed |
| 17 | 10730688 | Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. | Pharmacotherapy | 2000 | https://conductscience.org/library/papers/10730688 | PubMed |
| 18 | 15844071 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/15844071 | PubMed |
| 19 | 3628475 | Influence of the enzyme induction by rifampicin on its presystemic metabolism. | Pharmacol Ther | 1987 | https://conductscience.org/library/papers/3628475 | PubMed |
| 20 | 18092886 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. | PLoS Med | 2007 | https://conductscience.org/library/papers/18092886 | PubMed |
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42878247 | Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model-Based Analysis of Mother-Infant Pairs for Tuberculosis Prevention. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42878247 | PubMed |
| 41609968 | A Validated LC-MS/MS Method for Unbound Rifapentine Quantitation Reveals Nonlinear Plasma Protein Binding and Comparable Free Fractions Between Adults and Children with Tuberculosis. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/41609968 | PubMed |
| 41504451 | Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41504451 | PubMed |
| 41410856 | Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro Evidence. | Clin Drug Investig | 2026 | https://conductscience.org/library/papers/41410856 | PubMed |
| 41047272 | Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis. | BMJ Open | 2025 | https://conductscience.org/library/papers/41047272 | PubMed |
| 40990707 | New drugs for the management of tuberculosis. | Curr Opin Infect Dis | 2025 | https://conductscience.org/library/papers/40990707 | PubMed |
| 40560789 | Development and hepatotoxicity of rifamycin derivatives. | Expert Opin Drug Metab Toxicol | 2025 | https://conductscience.org/library/papers/40560789 | PubMed |
| 40080768 | Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial. | Am J Respir Crit Care Med | 2025 | https://conductscience.org/library/papers/40080768 | PubMed |
| 39477924 | Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. | Nat Commun | 2024 | https://conductscience.org/library/papers/39477924 | PubMed |
| 39240337 | Therapeutic drug monitoring in tuberculosis. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/39240337 | PubMed |
| 37855280 | An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions. | Med Chem | 2024 | https://conductscience.org/library/papers/37855280 | PubMed |
| 37321622 | Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. | Eur Respir J | 2023 | https://conductscience.org/library/papers/37321622 | PubMed |
| 37158831 | Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. | BMC Infect Dis | 2023 | https://conductscience.org/library/papers/37158831 | PubMed |
| 36778546 | Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in China. | Front Public Health | 2023 | https://conductscience.org/library/papers/36778546 | PubMed |
| 36588698 | Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36588698 | PubMed |
| 36516792 | New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians. | Respiration | 2023 | https://conductscience.org/library/papers/36516792 | PubMed |
| 35722783 | Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies. | Clin Transl Sci | 2022 | https://conductscience.org/library/papers/35722783 | PubMed |
| 35462285 | Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. | J Pharm Biomed Anal | 2022 | https://conductscience.org/library/papers/35462285 | PubMed |
| 35120633 | Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. | Lancet HIV | 2022 | https://conductscience.org/library/papers/35120633 | PubMed |
| 34623770 | Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/34623770 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| CYP4F3 | 4051 | PubTator's text mining | https://conductscience.org/library/genes/4051 | NCBI Gene |
| NR1I2 | 8856 | PubTator's text mining | https://conductscience.org/library/genes/8856 | NCBI Gene |
| SLCO1B1 | 10599 | PubTator's text mining | https://conductscience.org/library/genes/10599 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22472995
GET https://conductscience.org/api/papers/v1/22472995/references?page=2